- Price
- $207.78
- Day
- -3.03%
- Mkt Cap
- $10.69B
- 52W Range
- $114.91 – $260.19
- Volume
- 869.3K
- Beta
- 0.60
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Axsome Therapeutics NASDAQ: AXSM executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th Annual Global Investment Conference.
Read full article
Bank of America Corp DE bought a new stake in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 452,491 shares of the company's stock, valued at approximately $110,756,000. Bank of America Corp DE owned approximately
Read full article
Axsome Therapeutics NASDAQ: AXSM executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer's disease agitation, while management expects operating expenses to remain relatively stable in the second half of the year.
Read full article
Axsome Therapeutics is seeing significant revenue growth as its central nervous system portfolio gains commercial traction. Moderna is transitioning its mRNA platform toward a broader array of respiratory and oncology treatments to offset declining COVID-19 vaccine sales.
Read full article
Axsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercialized central nervous system treatments. Revolution Medicines is advancing a high-potential pipeline of RAS(ON) inhibitors aimed at treating some of the most difficult cancers.
Read full article
Axsome Therapeutics' revenue is growing at a good clip. The company has a deep pipeline as well.
Read full article
Axsome Therapeutics has launched exciting new drugs over the past year, and they are delivering growth. The biopharma player's late-stage pipeline could translate into additional products over the next few years.
Read full article
NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data in major depressive disorder and Alzheimer's disease agitation and eight additional encore data posters spanning its psychiatry and neurology portfolio at Psych Congress 2026, being held September 15-19, in New Orleans, Louisiana.
Read full article
Axsome Therapeutics, Inc. (AXSM) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
Read full article
Axsome Therapeutics, Inc. (AXSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Read full article
One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.
Read full article
Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Read full article